Simvastatin: A Reappraisal of its Pharmacology and Therapeutic Efficacy in Hypercholesterolaemia

Drugs

Volumn 50, Issue 2, 1995, Pages 334-363

  Plosker, Greg L ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

ASTHENIA; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG SAFETY; FOAM CELL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MACROPHAGE; MORBIDITY; MORTALITY; MYOSITIS; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SLEEP DISORDER; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CHOLESTEROL; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG TOLERANCE; FEMALE; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN;

EID: 0029092064     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550020-00009     Document Type: Article

References (239)

1. Simvastatin: a review of its pharmacological properties and therapeutic potential in hyperchlosterolaemia
2. Effects of HMG CoA reductase inhibitors on cholesterol synthesis
3. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin
4. Non-cholesterol sterols and faecal elimination of cholesterol during statin and fibrate treatment
5. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells
6. Effects of simvastatin (MK-733) on branched pathway of mevalonate
7. Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes
8. Effetti della simvastatina sulle lipoproteine plasmatiche
9. Simvastatin in the treatment of hypercholesterolemia in elderly patients
10. Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia
11. Effectiveness and tolerability of simvastatin in subjects with primary hypercholesterolemia. Multicenter study [in Italian]
12. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease
13. Comparative effects of pravastatin, simvastatin, fenofibrate and cholestyramine on plasma apolipoprotein AI containing plasma lipoprotein particles
14. Effects of simvastatin on ApoB metabolism and LDL subfraction distribution
15. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia
16. Effect of simvastatin therapy on apolipoproteins
17. National cholesterol education program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
18. Simvastatin and lipoprotein(a)
19. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin
20. Mechanism of action and biological profile of HMG CoA reductase inhibitors: a new therapeutic approach
21. Lipoprotein receptors in the liver control signals for plasma cholesterol traffic
22. Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hyper-cholesterolemia induced by cholesterol feeding in rabbits
23. Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit
24. Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs
25. The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells
26. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia
27. Effects of MK-733, an inhibiotr of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, on absorption and excretion of 3H chosterol in rabbits
28. Effect of simvastatin (MK-733) on sterol and bile acid excretion in rabbits
29. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors
30. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects
31. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in chosterol-fed rabbits: a biochemical and morphological evaluation
32. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes
33. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation
34. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase
35. Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits
36. Preventative effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits
37. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normo-cholesterolemic rabbits
38. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
39. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
40. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
41. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
42. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS)
43. Effects of hydroxy-methylglutaryl-coenzyme A reductase inhibitors on some blood coagulation parameters
44. Plasma fibrinogen levels in hypercholesterolemia: effects of simvastatin therapy
45. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents
46. Modifications of the coagulative and rheologic pattern in hypercholesterolemic patients treated with bezafibrate R or simvastatin
47. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
48. The effect of treatment with simvastatin on platelet function indices in hypercholesterolaemia
49. Platelet reactivity, effects of simvastatin therapy [abstract]
50. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
51. A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters
52. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity
53. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients
54. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients
55. Cortisol secretion in patients on simvastatin
56. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones
57. Adrenocortical function in patients on simvastatin [letter; comment]
58. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia
59. Simvastatin influences testicular steroidogenesis in human [letter]
60. 10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylgultaryl coenzyme A reductase inhibitors
61. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia
62. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
63. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
64. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin
65. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile
66. Effect of simvastatin, urso-deoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia
67. Clinical pharmacokinetics and practical applications of simvastatin
68. Metabolic disposition of simvastatin in patients with T-tube drainage
69. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans
70. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
71. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
72. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
73. A quarter centruy of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin
74. Regioselectivity and stereo-selectivity in the metabolism of HMG-CoA reductase inhibitors
75. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase
76. Management of hyperlipidaemia: guidelines of the British hyperlipidaemia association
77. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
78. Multiple risk factor intervention trial
79. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease
80. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
81. Change in cholesterol awareness and action: results from national physician and public surveys
82. Epidemiology of hypercholesterolemia and European management guidelines
83. Gender and diet interactions with simvastatin treatment
84. Effect of simvastatin treatment on high-density lipoprotein cholesterol
85. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
86. Simvastatin in the treatment of primary hypercholesterolemia. Interim results of the German Multicenter Simvastatin Study [in German]
87. Effectiveness and tolerability of simvastatin in patients with moderate or severe hypercholesterolemia. Results after 12 months of treatment [in Italian]
88. Clinical effect of MK-733 (simvastatin) on hyperlipidemia — results of multiclinical open study
89. A one-year multicentre study of simvastatin in the treatment of hyper-cholesterolaemia
90. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks
91. Clinical evaluation of simvastatin in patients with severe hypercholesterolemia. An Italian open study
92. A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia
93. Using changes in attributable risk to predict long-term efficacy of simvastatin treatment
94. Correspondence
95. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia
96. Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis [in Portuguese]
97. Simvastatin in the treatment of hypercholesterolemia in geriatrics
98. Effects of therapy with diet and simvastatin on atherosclerosis in hyper-cholesterolemic patients
99. A multicenter Italian study on the efficacy and tolerability of simvastatin in male patients with essential hypertension and primary hypercholesterolemia [abstract]
100. Effects of simvastatin on the escape phenomenon following pravastatin therapy in patients with hypercholesterolemia [abstract]
101. Long-term effects of simvastatin in familial dysbetalipoproteinaemia
102. Simvastatin use in children [letter]
103. The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia
104. Conventional vs low doses simvastatin for treating hypercholesterolemic essential hypertensives [abstract]
105. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study
106. Correspondence
107. Dose-response of simvastatin in primary hypercholesterolemia
108. Efficacy and tolerability of simvastatin (epistatin) in the elderly
109. The clinical efficacy and safety of lovastatin and MK-733 — an overview
110. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study
111. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study
112. A double-blind twelve-week placebo-controlled study to assess the efficacy of simvastatin in the treatment of hypercholesterolaemia in hypertensive patients
113. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial
114. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)
115. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis
116. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia
117. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolaemia
118. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia
119. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. (Multicountry comparative study)
120. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
121. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia
122. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia
123. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin
124. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study
125. The efficacy and safety of pravastatin and simvastatin in patients with primary hyper-cholesterolemia
126. Comparison of different HMG-CoA reductase inhibitors
127. Effectiveness and tolerability of simvastatin versus pravastatin
128. Long term treatment with pravastatin, simvastatin and gemfibrozil in patients with primary hypercholesterolaemia: a controlled study
129. Effects of HMG Co-A reductase inhibitors on lipids and lipoprotein (a) in hypercholesterolaemia
130. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
131. A review of clinical trials comparing HMG-CoA reductase inhibitors
132. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol
133. Reductions in lipid fraction plasma levels induced by simvastatin and bezafibrate. Brazilian multicenter study [in Portuguese]
134. Comparative multicentre trial of the efficacy and tolerability of ciprofibrate and simvastatin in the treatment of mixed type IIB hyperlipoprotein-aemias
135. Comparison of simvastatin and ciprofibrate in the treatment of primary hypercholesterolaemia — a French multicentre study
136. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
137. Effectiveness and tolerability of simvastatin and fenofibrate in primary hypercholesterolemia [in French]
138. Gemfibrozil versus simvastatin in primary moderate hypercholesterolemia with low high-density lipoprotein cholesterol: a multicenter comparison
139. Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide [in Italian]
140. Comparison of gemfibrozil versus simvastatin in familial combined hyper-lipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability
141. Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia [in French]
142. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
143. Comparison of the efficacy and value of bezafibrate and simvastatin in mixed hyperlipidemia [in French]
144. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia
145. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins
146. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia
147. Sequential management of hypercholesterolaemia with a fibrate and simvastatin. The Belgian general practitioners’ trial
148. Cholesterol reduction yields clinical benefit: a new look at old data
149. Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia
150. Addition of fibrates to simvastatin therapy in hyperlipidaemic patients
151. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia
152. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia
153. Effects and side effects of one-year treatment of hypercholesterolemia with simvastatin [in German]
154. Clinical implications of new drugs for lowering plasma cholesterol concentrations
155. Efficacy of simvastatin plus cholestyramine in the two-year treatment of heterozygous hypercholesterolemia
156. Lecithin: cholesterol acyl-transferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol
157. HMG-CoA reductase inhibitors in familial hypercholesterolemia
158. Pharmacological therapy for hypercholesterolaemia in patients with familial defective apolipoprotein B 100 [in German]
159. Treatment of hypercholesterolemic patients of different age with simvastatin: 1-year study [in Italian]
160. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol
161. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting
162. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures
163. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
164. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics
165. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus [abstract]
166. Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia
167. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus
168. Use and effect of simvastatin in type II diabetics [in Italian]
169. Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia
170. Diabetes mellitus, hypercholesterolemia and therapeutic possibilities with simvastatin. General appraisal and personal experience [in Italian]
171. Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia
172. Effect of simvastatin on serum lipids, lipoproteins, apolipoproteins and pot-heparin plasma lipoprotein lipase activity in patients with non-insulin-dependent diabetes mellitus
173. Long-term effects of low-dose simvastatin in hypercholesterolemic type 2 diabetic patients
174. Long-term treatment with simvastatin in hypercholesterolemic non-insulin-dependent diabetic patients
175. Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels
176. Efficacy and safety of simvastatin for the treatment of hypercholesterolemia in patients with and without type II diabetes
177. Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus and in primary hypercholesterolemia
178. The effects of the cholesterol synthesis inhibitor simvastatin in patients with hypercholesterolemia with and without diabetes mellitus [in Dutch]
179. Comparison of simvastatin vs gemfibrozil therapy on lipid, glycaemic and haemorheological parameters in Type-II diabetes-mellitus
180. Treatment of nephrotic syndrome hyperlipidemia with simvastatin
181. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome
182. Partial remission of nephrotic syndrome in patient on long-term simvastatin [letter]
183. A clinical trial comparing the treatment of hypercholesterolemia with simvastatin and diet versus diet alone in patients with idiopathic membranous nephropathy. A preliminary report [abstract]
184. Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN)
185. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria
186. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome
187. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome
188. Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin [letter]
189. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
190. Effect of simvastatin in CAPD patients with hypercholesterolemia
191. Therapeutic effects of simvastatin on hyperlipidemia in CAPD patients
192. Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis
193. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients
194. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients
195. Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment [in Italian]
196. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
197. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients
198. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hyper-cholesterolemia after renal transplantation
199. Hypercholesterolemia treatment in a renal transplant patient [letter]
200. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients
201. Simvastatin therapy of hypercholesterolemia associated with chronic rejection after renal transplantation. A prospective study [abstract]
202. Simvastatin. A pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease
203. Cost-effectiveness of drug therapy for hypercholesterolaemia. A review of the literature
204. Cost-effectiveness of simvastatin versus cholestyramine. Results for Sweden
205. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors
206. Effect of biological and analytical variation in cholesterol measurement on the cost-effectiveness of cholesterol-lowering therapy
207. Long term experience with simvastatin
208. Extended worldwide experience HMG-CoA reductase inhibitors lovastatin and simvastatin [in French]
209. Adverse reactions profile: 10. Simvastatin and pravastatin
210. Skin lesions due to treatment with simvastatin (Zocor ®)
211. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors
212. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia
213. Long-term experience with pravastatin in clinical research trials
214. The long-term tolerability profile of lovastatin and simvastatin
215. Long-term safety of fibrate-statin combination therapy in the treatment of hypercholesterolaemia [abstract]
216. Rhabdomyolysis with simvastatin use
217. Rhabdomyolysis with simvastatin: report of a case [in French]
218. Massive rhabdomyolysis and simvastatin [letter]
219. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome
220. Rhabdomyolysis and simvastatin
221. Simvastatin-induced rhabdomyolysis. Report of a case with a review of the literature [in French]
222. Simvastatin-induced rhabdomyolysis in a heart transplant recipient receiving cyclosporin [in French]
223. Rhabdomyolysis and renal injury with lovastatin use
224. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias
225. Efficacy and long term adverse effect pattern of lovastatin
226. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
227. Worldwide experience with simvastatin/lovastatin
228. Long-term clinical tolerance of lovastatin and simvastatin
229. Long-term safety and efficacy profile of simvastatin
230. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up
231. Lens opacity: five year follow-up of patients with hypercholesterolemia receiving simvastatin treatment
232. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years
233. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia
234. The HMG-CoA reductase inhibitors, simvastatin and pravastatin. No evidence of side effects in eyes in use in humans [in German]